Drug intelligence / Profile preview

TRN-003

Development stage: Preclinical
Lead developer: Turn Biotechnologies
Modality: Small Molecules, Vaccines & Immunotherapeutics
Administration: Ophthalmic

Overview

TRN-003 is an investigational RNA interference (RNAi) drug being developed by Turn Biotechnologies for the treatment of glaucoma. It is designed as a formulation to address eye diseases, specifically targeting glaucoma, and is currently in preclinical development. The mechanism of action involves RNA interference, which allows for the silencing of specific gene expression related to disease pathology[1][2].

Beyond the preview

Go deeper on TRN-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRN-003.

Explore the full profile